AMEDISYS INC (AMED) Stock Fundamental Analysis
NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
Overall AMED gets a fundamental rating of 5 out of 10. We evaluated AMED against 109 industry peers in the Health Care Providers & Services industry. AMED scores excellent on profitability, but there are some minor concerns on its financial health. AMED is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AMED was profitable.
In the past year AMED had a positive cash flow from operations.
AMED had positive earnings in 4 of the past 5 years.
In the past 5 years AMED always reported a positive cash flow from operatings.
1.2 Ratios
AMED has a better Return On Assets (3.88%) than 75.00% of its industry peers.
With a decent Return On Equity value of 7.23%, AMED is doing good in the industry, outperforming 70.37% of the companies in the same industry.
With an excellent Return On Invested Capital value of 9.98%, AMED belongs to the best of the industry, outperforming 87.04% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for AMED is above the industry average of 8.15%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.88% | ||
| ROE | 7.23% | ||
| ROIC | 9.98% |
ROA(3y)5.6%
ROA(5y)7.71%
ROE(3y)10.94%
ROE(5y)15.06%
ROIC(3y)11.18%
ROIC(5y)12.42%
1.3 Margins
AMED has a better Profit Margin (3.57%) than 75.93% of its industry peers.
AMED's Operating Margin of 9.00% is amongst the best of the industry. AMED outperforms 81.48% of its industry peers.
AMED's Operating Margin has declined in the last couple of years.
AMED has a better Gross Margin (43.67%) than 71.30% of its industry peers.
In the last couple of years the Gross Margin of AMED has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9% | ||
| PM (TTM) | 3.57% | ||
| GM | 43.67% |
OM growth 3Y-1.84%
OM growth 5Y-1.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.18%
GM growth 5Y1.92%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMED is creating some value.
Compared to 1 year ago, AMED has more shares outstanding
The number of shares outstanding for AMED has been increased compared to 5 years ago.
AMED has a better debt/assets ratio than last year.
2.2 Solvency
AMED has an Altman-Z score of 3.82. This indicates that AMED is financially healthy and has little risk of bankruptcy at the moment.
AMED has a better Altman-Z score (3.82) than 75.00% of its industry peers.
AMED has a debt to FCF ratio of 1.88. This is a very positive value and a sign of high solvency as it would only need 1.88 years to pay back of all of its debts.
The Debt to FCF ratio of AMED (1.88) is better than 84.26% of its industry peers.
A Debt/Equity ratio of 0.30 indicates that AMED is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.30, AMED is doing good in the industry, outperforming 63.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.88 | ||
| Altman-Z | 3.82 |
ROIC/WACC1.14
WACC8.74%
2.3 Liquidity
AMED has a Current Ratio of 1.19. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of AMED (1.19) is worse than 65.74% of its industry peers.
A Quick Ratio of 1.19 indicates that AMED should not have too much problems paying its short term obligations.
AMED has a Quick ratio (1.19) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
AMED shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.88%.
AMED shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.28% yearly.
The Revenue has been growing slightly by 4.19% in the past year.
The Revenue has been growing slightly by 6.11% on average over the past years.
EPS 1Y (TTM)-4.88%
EPS 3Y-11.17%
EPS 5Y3.28%
EPS Q2Q%2.04%
Revenue 1Y (TTM)4.19%
Revenue growth 3Y2.59%
Revenue growth 5Y6.11%
Sales Q2Q%5.65%
3.2 Future
Based on estimates for the next years, AMED will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.42% on average per year.
Based on estimates for the next years, AMED will show a small growth in Revenue. The Revenue will grow by 5.43% on average per year.
EPS Next Y4.38%
EPS Next 2Y8.14%
EPS Next 3Y8.42%
EPS Next 5YN/A
Revenue Next Year5.09%
Revenue Next 2Y5.13%
Revenue Next 3Y5.43%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AMED is valuated rather expensively with a Price/Earnings ratio of 21.56.
70.37% of the companies in the same industry are more expensive than AMED, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 28.46. AMED is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 18.44, which indicates a rather expensive current valuation of AMED.
Based on the Price/Forward Earnings ratio, AMED is valued a bit cheaper than the industry average as 67.59% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 92.56, AMED is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.56 | ||
| Fwd PE | 18.44 |
4.2 Price Multiples
AMED's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AMED is cheaper than 62.96% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMED is valued cheaper than 85.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.89 | ||
| EV/EBITDA | 13.51 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of AMED may justify a higher PE ratio.
PEG (NY)4.93
PEG (5Y)6.57
EPS Next 2Y8.14%
EPS Next 3Y8.42%
5. Dividend
5.1 Amount
AMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMEDISYS INC
NASDAQ:AMED (1/31/2025, 8:10:40 PM)
After market: 92.5 0 (0%)92.5
+0.09 (+0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners94.06%
Inst Owner Change1.79%
Ins Owners2.08%
Ins Owner Change-0.13%
Market Cap3.03B
Analysts53.75
Price Target99.32 (7.37%)
Short Float %7.02%
Short Ratio3.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.39%
Min EPS beat(2)-15.99%
Max EPS beat(2)9.21%
EPS beat(4)1
Avg EPS beat(4)-4.61%
Min EPS beat(4)-15.99%
Max EPS beat(4)9.21%
EPS beat(8)4
Avg EPS beat(8)2.21%
EPS beat(12)6
Avg EPS beat(12)2.76%
EPS beat(16)8
Avg EPS beat(16)2.98%
Revenue beat(2)1
Avg Revenue beat(2)-0.95%
Min Revenue beat(2)-2.02%
Max Revenue beat(2)0.13%
Revenue beat(4)1
Avg Revenue beat(4)-1.06%
Min Revenue beat(4)-2.02%
Max Revenue beat(4)0.13%
Revenue beat(8)1
Avg Revenue beat(8)-2.04%
Revenue beat(12)1
Avg Revenue beat(12)-2.8%
Revenue beat(16)1
Avg Revenue beat(16)-2.89%
PT rev (1m)0%
PT rev (3m)-0.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.22%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.56 | ||
| Fwd PE | 18.44 | ||
| P/S | 1.31 | ||
| P/FCF | 14.89 | ||
| P/OCF | 14.31 | ||
| P/B | 2.64 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.51 |
EPS(TTM)4.29
EY4.64%
EPS(NY)5.02
Fwd EY5.42%
FCF(TTM)6.21
FCFY6.72%
OCF(TTM)6.46
OCFY6.99%
SpS70.87
BVpS35.05
TBVpS-6
PEG (NY)4.93
PEG (5Y)6.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.88% | ||
| ROE | 7.23% | ||
| ROCE | 12.64% | ||
| ROIC | 9.98% | ||
| ROICexc | 11.73% | ||
| ROICexgc | 260.89% | ||
| OM | 9% | ||
| PM (TTM) | 3.57% | ||
| GM | 43.67% | ||
| FCFM | 8.77% |
ROA(3y)5.6%
ROA(5y)7.71%
ROE(3y)10.94%
ROE(5y)15.06%
ROIC(3y)11.18%
ROIC(5y)12.42%
ROICexc(3y)11.68%
ROICexc(5y)13.03%
ROICexgc(3y)125.73%
ROICexgc(5y)225.54%
ROCE(3y)14.15%
ROCE(5y)15.72%
ROICexcg growth 3Y-41.4%
ROICexcg growth 5Y2.18%
ROICexc growth 3Y-10.39%
ROICexc growth 5Y-16.56%
OM growth 3Y-1.84%
OM growth 5Y-1.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.18%
GM growth 5Y1.92%
F-Score6
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.88 | ||
| Debt/EBITDA | 1.47 | ||
| Cap/Depr | 32.46% | ||
| Cap/Sales | 0.35% | ||
| Interest Coverage | 6.3 | ||
| Cash Conversion | 90.42% | ||
| Profit Quality | 245.38% | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 3.82 |
F-Score6
WACC8.74%
ROIC/WACC1.14
Cap/Depr(3y)34.64%
Cap/Depr(5y)33.05%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.88%
EPS 3Y-11.17%
EPS 5Y3.28%
EPS Q2Q%2.04%
EPS Next Y4.38%
EPS Next 2Y8.14%
EPS Next 3Y8.42%
EPS Next 5YN/A
Revenue 1Y (TTM)4.19%
Revenue growth 3Y2.59%
Revenue growth 5Y6.11%
Sales Q2Q%5.65%
Revenue Next Year5.09%
Revenue Next 2Y5.13%
Revenue Next 3Y5.43%
Revenue Next 5YN/A
EBIT growth 1Y19.66%
EBIT growth 3Y0.69%
EBIT growth 5Y4.48%
EBIT Next Year23.3%
EBIT Next 3Y12.65%
EBIT Next 5YN/A
FCF growth 1Y123.63%
FCF growth 3Y-24.01%
FCF growth 5Y-10.51%
OCF growth 1Y116.88%
OCF growth 3Y-21.99%
OCF growth 5Y-9.3%